

Helix Tier One Population Screen

Patient Name: Jane Doe	Patient ID: 96138	Provider Name: Client Client	Order Date: 01-01-2026
Date of Birth: 02-20-1992	Helix ID: TST12345	Collection Date: 01-01-2026	Report Date: 01-26-2026

Results POSITIVE

Classification	Gene	DNA Change	Protein Change	Zygoty	Inheritance
PATHOGENIC	BRCA2	c.7558C>T	p.Arg2520Ter	Heterozygous	AD

One Pathogenic variant was detected in the BRCA2 gene. These results indicate a predisposition to, or diagnosis of, autosomal dominant hereditary breast and ovarian cancer syndrome. These results also indicate carrier status for autosomal recessive Fanconi anemia.

The BRCA2 gene is associated with the following condition(s):

- autosomal dominant hereditary breast and ovarian cancer syndrome (HBOC) (MedGen UID: 382625)
- autosomal recessive Fanconi anemia, type D1 (FA) (MedGen UID: 325420)

Having one pathogenic variant in the BRCA2 gene is associated with autosomal dominant HBOC, an adult-onset condition that causes an increased risk of certain cancers, particularly breast and ovarian in females, although affected males have cancer risks as well.

- BRCA2-associated cancer risks include: breast cancer, 44–61% lifetime risk in biological females; contralateral breast cancer (the chance of later developing breast cancer in their other breast) within 10 years after the first diagnosis, 11–35%; male breast cancer, 4–7% risk; ovarian or fallopian tube cancer, 11–20% lifetime risk in biological females; pancreatic cancer, 4–6% lifetime risk; prostate cancer, 28% lifetime risk in biological males; it is unclear whether lifetime risk is significantly increased above the general population for skin cancer (melanoma).

Having two pathogenic variants in BRCA2, one in each copy of the gene, is associated with autosomal recessive FA. FA is a rare, childhood-onset condition that affects various parts of the body with symptoms including short stature, a small head size (microcephaly), developmental delay, abnormal skin pigmentation, scoliosis, abnormally formed bones, and frequent infections due to a weakened immune system. There is also significant impact to the bone marrow's ability to form blood cells including platelets leading to fatigue and easy bruising and bleeding in addition to an increased risk of blood cancer (acute myeloid leukemia) and malignant solid tumors of the head and neck, skin, and genitourinary tract.

The age of onset, severity, and types of symptoms associated with BRCA2-associated conditions can vary widely, even among affected individuals from the same family.

MEDICAL MANAGEMENT recommendations and/or guidelines are available for BRCA2-related condition(s): <https://www.nccn.org/>, PMID: 36485157, https://www.fanconi.org/images/uploads/other/Fanconi_Anemia_Clinical_Care_Guidelines_5thEdition_web.pdf
 REFERENCES: PMID: 32676552, 33471974, 33471991, 26700119, 20204502, 15197194, 18042939, 35077220, 25849179, 28632866, 23099806, 30900310, 31495749, 25524463

Biological family members may be at risk for developing autosomal dominant hereditary breast and ovarian cancer syndrome and are at risk for, or may be carriers of, autosomal recessive Fanconi anemia.

Genetic test results should be interpreted in the context of an individual's personal medical and family history. Genetic counseling is recommended. Clinical correlation is advised.

Additional Considerations

- This is a screening test; individuals may still carry pathogenic or likely pathogenic variant(s) in the tested genes that are not detected by this test.
- For individuals at risk for these or other related conditions based on factors including personal or family history, diagnostic testing is recommended.
- The Variant Interpretation section below may provide additional details regarding the reported variant(s).
- The absence of pathogenic or likely pathogenic variant(s) in any of the other analyzed genes, while reassuring, does not eliminate the possibility of a hereditary condition; there are other variants and genes associated with heart disease and hereditary cancer that are not included in this test.

Test Description

Helix Tier One Population Screen is a screening test that analyzes 11 genes related to hereditary breast and ovarian cancer (HBOC) syndrome, Lynch syndrome, and familial hypercholesterolemia. This test only reports clinically significant pathogenic and likely pathogenic variants but does not report variants of uncertain significance (VUS). In addition, analysis of the PMS2 gene excludes exons 11–15, which overlap with a known pseudogene (PMS2CL).

Genes Tested

APOB, BRCA1, BRCA2, EPCAM, LDLR, LDLRAP1, PCSK9, PMS2, MLH1, MSH2, MSH6

Helix Tier One Population Screen

Patient Name: Jane Doe	Patient ID: 96138	Provider Name: Client Client	Order Date: 01-01-2026
Date of Birth: 02-20-1992	Helix ID: TST12345	Collection Date: 01-01-2026	Report Date: 01-26-2026

Classification	Gene	DNA Change	Protein Change	Zygosity	Inheritance
PATHOGENIC	BRCA2	c.7558C>T	p.Arg2520Ter	Heterozygous	AD

Transcript: NM_000059.4	Genomic Change: NC_000013.11:g.32356550C>T
----------------------------	---

Variant Interpretation

This variant (NM_000059.4:c.7558C>T p.Arg2520Ter) results in the creation of a premature stop codon in the BRCA2 gene. This variant is predicted to result in nonsense-mediated mRNA decay or in the production of a truncated protein, leading to loss-of-function (LOF). LOF variants in the BRCA2 gene are known to be deleterious (PMID: 20104584, 20301575). This variant is also known as 7786C>T. It is present in the non-cancer cohort of the gnomAD population database (PMID: 32461654) at the highest allele frequency in Admixed Americans among continental populations (1/34248 alleles, 0.00292%). This variant has been observed in numerous individuals affected with BRCA2-associated cancers (PMID: 9150154, 21990299, 22009639, 24959366, 33471991). Clinical laboratory interpretations available in ClinVar are in broad agreement that this variant is Pathogenic (ClinVar Variation ID: 52353). The most relevant articles have been cited but the list is not exhaustive. In conclusion, this variant has been classified as Pathogenic.

Methods & Limitations

Extracted DNA is enriched for targeted regions and then sequenced using the Helix Exome+ (R) assay on an Illumina DNA sequencing system. Data is then aligned to a modified version of GRCh38 and all genes are analyzed using the MANE transcript and MANE Plus Clinical transcript, when available. Small variant calling is completed using a customized version of Sentieon's DNaseq software, augmented by a proprietary small variant caller for difficult variants. Copy number variants (CNVs) are then called using a proprietary bioinformatics pipeline based on depth analysis with a comparison to similarly sequenced samples. Analysis of the PMS2 gene is limited to exons 1-10. Both the MSH2 Boland inversion (exons 1-7) and the BRCA2 Alu insertion are detected by identifying discordant read-pairs spanning the breakpoints. The interpretation and reporting of variants in APOB, PCSK9, and LDLR is specific to familial hypercholesterolemia; variants associated with hypobetalipoproteinemia are not included. Interpretation is based upon guidelines published by the American College of Medical Genetics and Genomics (ACMG), the Association for Molecular Pathology (AMP) or their modification by ClinGen Variant Curation Expert Panels when available and/or review of previous clinical assertions available in the ClinVar database. Interpretation is limited to the transcripts indicated on the report and +/- 10 bp into intronic regions, except as noted below. Helix variant classifications include pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, and benign. Only variants classified as pathogenic and likely pathogenic are included in the report. All reported variants are confirmed through secondary manual inspection of DNA sequence data or orthogonal testing. Risk estimations and management guidelines included in this report are based on analysis of primary literature and recommendations of applicable professional societies, and should be regarded as approximations.

Based on validation studies, this assay delivers > 99% sensitivity and specificity for single nucleotide variants and insertions and deletions (indels) up to 20 bp. Larger indels and complex variants are also reported but sensitivity may be reduced. Based on validation studies, this assay delivers > 99% sensitivity to multi-exon CNVs and > 90% sensitivity to single-exon CNVs. This test may not detect variants in challenging regions (such as short tandem repeats, homopolymer runs, and segment duplications), sub-exonic CNVs, chromosomal aneuploidy, or variants in the presence of mosaicism. Phasing will be attempted and reported, when possible. Structural rearrangements such as inversions, translocations, complex rearrangements, and gene conversions are not tested in this assay unless explicitly indicated. Additionally, deep intronic, promoter, and enhancer regions may not be covered. It is important to note that this is a screening test and cannot detect all disease-causing variants. A negative result does not guarantee the absence of a rare, undetectable variant in the genes analyzed; consider using a diagnostic test if there is significant personal and/or family history of one of the conditions analyzed by this test. Any potential incidental findings outside of these genes and conditions will not be identified, nor reported. The results of a genetic test may be influenced by various factors, including bone marrow transplantation, blood transfusions, or in rare cases, hematolymphoid neoplasms.

Gene Specific Notes:

APOB: analysis is limited to c.10580G>A and c.10579C>T; BRCA1: sequencing analysis extends to CDS +/-20 bp; BRCA2: analysis includes detection of c.156_157insAlu and sequencing analysis extends to CDS +/-20 bp. EPCAM: analysis is limited to CNV of exons 8-9; LDLR: analysis includes CNV of the promoter; MLH1: analysis includes CNV of the promoter; MSH2: analysis includes detection of the Boland inversion (inversion of exons 1-7) and detection of c.942+3A>T, PMS2: analysis is limited to exons 1-10.

Helix Tier One Population Screen

Patient Name: Jane Doe	Patient ID: 96138	Provider Name: Client Client	Order Date: 01-01-2026
Date of Birth: 02-20-1992	Helix ID: TST12345	Collection Date: 01-01-2026	Report Date: 01-26-2026

Disclaimer

This test was developed and validated by Helix, Inc. This test has not been cleared or approved by the United States Food and Drug Administration (FDA). The Helix laboratory is accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA #: 05D2117342) to perform high-complexity clinical tests. This test is used for clinical purposes. It should not be regarded as investigational use only or for research use only.

Report Signed By

Matt Ferber, Ph.D. FACMG

Helix's Sequence Once, Query Often® Model

When your provider orders a genetic test through Helix, we use our proprietary Sequence Once, Query Often® model to perform whole exome sequencing and analyze the specific genes related to the test. Helix securely stores your whole exome for future clinical use. With your permission, this allows your health care providers to order future medically necessary genetic tests from Helix without needing another sample. Instead, these tests are conducted through digital analysis of your stored genetic information.

To learn more about how Helix protects the privacy and security of your genetic information and learn more about your rights, please visit <https://www.helix.com/privacy-and-policy-highlights>.

SAMPLE